MMS Poised for an Innovative Future with Best Clinical Research Organization Award and Two Key Executive Appointments

CANTON, Mich.–(BUSINESS WIRE)–#biotech–MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced the growth of its leadership team with the appointment of Kelly J. Hill to Executive Vice President (EVP) of Global Business Operations and Strategy and Michelle Gayari to Executive Vice President of Global Operational Excellence and Innovation. This comes as the company was awarded Best Data-Focused Biotech CRO in the International Life Sciences Awards.

Hill and Gayari are long-time members of the executive leadership team at MMS, which has remained steadfast and unchanged for the past decade. Both EVPs are Pfizer alumni and, along with Chief Scientific Officer and Founder Dr. Uma Sharma, who began growing MMS into a global powerhouse after Pfizer closed its Ann Arbor doors in 2007.

“We are grateful for Kelly and Michelle’s contributions to MMS, and their sense of urgency and leadership has allowed us to considerably expand our teams and company globally,” said Prasad M. Koppolu, Chief Operating Officer, MMS.

Organic growth

MMS has maintained strong, organic growth since its inception, and these most recent promotions reflect that. Hill and Gayari have been instrumental in leading company advancements, including expanding services, acquiring new clients, and implementing the USD1M award for COVID-19 vaccine development that MMS announced last year.

In recent weeks, MMS surpassed a total of 800 colleagues across North America, Asia, Europe, and South Africa.

“I’m grateful for this opportunity to continue building the MMS brand and bringing added value to Sponsor partners through strong teamwork and best-in-class tech-enabled services,” said Hill.

Technology-focused future

“The colleagues of MMS are proven innovators, and I am grateful to be a part of developing our diverse technology platforms to bring solutions to the industry and our clients,” said Gayari. “There is much more to come, and I’m excited to share these innovations with the industry.”

This year, MMS will conduct its second annual Global Champions of Change Competition (G3C) in an effort to bring forth innovations from every level of the organization. The company currently has eight new innovations underway from the inaugural event, in addition to innovations in data science, medical writing, clinical trial transparency, and pharmacovigilance that are already in use by global sponsors.

Learn more about our leadership and expertise at https://www.mmsholdings.com/executive-leadership/

ABOUT MMS

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the last three consecutive years.

For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.

Contacts

Don F. McLean

[email protected]
734-245-0165